PitchSend

Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Group operating performance Core OP up +9% driven by higher gross profit and ROOI, OPEX stable Roche CER-Constant Exchange Rates 2022 CHFM abs. CER 2022 vs. 2021 CER growth Sales 32,295 +1,672 5% Royalties & other op. inc. 1,943 +536 38% Cost of sales -9,305 -1,119 14% M & D -4,459 -159 4% R & D -6,628 +85 -1% G & A -1,178 +63 -5% Core operating profit 12,668 +1,078 9% +9% in CHF 55

View entire presentation